Engineered immune cells take aim at childhood cancers in early trial

This early-stage study tests a personalized cell therapy for children and young adults (ages 1–30) with solid tumors that have come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to recognize and attack tumors that carry a protein called EGFR. The study's main goals are to check safety, find the best dose, and see if the cells can persist in the body. It is not a cure, as the treatment aims to control the disease rather than eliminate the need for ongoing care.